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Abstract
AIM: To explore the association between TCF7L2  
rs12255372 and rs7903146 single nucleotide poly-
morphisms (SNPs) and gastric cancer risk in Venezuelan 
patients.
METHODS: We performed a case-control study 
including 122 paraffin-embedded archived intestinal-
type gastric cancer samples and 129 biopsies obtained 
by superior endoscopy from chronic gastritis patients. 
Gastric cancer samples were classified according the 
degree of carcinoma differentiation. Genomic DNA was 
extracted from tissues, and the two SNPs of TCF7L2  
gene (rs12255372 and rs7903146) were genotyped by 
polymerase chain reaction-restriction fragment length 
polymorphism reactions. Multiple regression analysis 
with adjustments for age and gender were performed 
and best-fitting models of inheritance were determined. 
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Case Control Study
TCF7L2 rs7903146 polymorphism is associated with gastric 
cancer: a case-control study in the Venezuelan population
mobility group box-containing transcription factor, 
which acts as an effector of the Wnt/β-catenin 
signaling pathway, therefore playing a pivotal role in 
cell development and growth regulation[2-4].
The TCF7L2 protein is also involved in blood glucose 
homeostasis, and their gene variants rs7903146 
(C>T) and rs12255372 (G>T) [it is in high linkage 
disequilibrium (LD) with rs7903146] are among the 
most significant genetic factors influencing the risk 
for type 2 diabetes (T2DM)[5-7]. Although the specific 
role of TCF7L2 in the development of T2DM is still 
being investigated, evidence indicates that alterations 
in the Wnt signaling pathway affect insulin secretion 
through the reduction of the GLP-1 production[8,9]. 
Moreover, aberrant Wnt signaling is involved in the 
pathogenesis of numerous types of human cancers[10], 
and particularly to the development and progression of 
gastric cancer[11].
Although with contradictory conclusions, several 
studies have studied the association between TCF7L2 
rs7903146 and rs12255372 single nucleotide poly-
morphisms (SNP) with susceptibility to several types 
of cancer, including in the prostate, breast, colon, 
rectum, lung and ovary[11-21]. However, to the best of 
our knowledge, the participation of these SNPs in the 
susceptibility of gastric cancer has not been evaluated 
yet.
Here, we present a case-control study carried out 
to evaluate the role of rs7903146 and rs12255372 
polymorphisms in the risk of gastric cancer in the 
Venezuelan population where gastric cancer is the 
leading cause of death due to cancer (http://www.
mpps.gob.ve/). 
MATERIALS AND METHODS
Subjects
A total number of 122 gastric cancer cases and 129 
controls were included in this study. The group of 
cases consisted of paraffin-embedded intestinal-
type gastric cancer samples according to Laurén’s 
classification, which were obtained from the Pathology 
Department Service of the Hospital Antonio María 
Pineda (HAMP), Barquisimeto, Venezuela. Tumor 
samples were classified into well differentiated, 
moderately differentiated and poorly differentiated 
cancer depending on the degree of differentiation of 
the cancerous cells[22].
Patients diagnosed with chronic gastritis without 
evidence of gastric cancer constituted the control group. 
Chronic gastritis samples obtained from patients with 
criteria for indication of endoscopy (Gastroenterology 
Service of the HAMP) were evaluated according to the 
Sydney classification system in regard to the presence 
and degree of atrophic gastritis, granulocytic infiltration 
and lymphocytic infiltration. Two independent experts 
in pathology from the Department of Pathology (HAMP) 
evaluated all biopsies. The Bioethics Committee of the 
School of Health Sciences, Universidad Centroccidental 
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Statistic powers were post-hoc calculated.
RESULTS: After adjusting for age and sex the 
TCF7L2  rs7903146 TT genotype was associated with 
gastric cancer risk under the recessive genetic model 
(OR = 3.11, 95%CI: 1.22-7.92, P  = 0.017). We 
further investigated the distribution of rs12255372 
and rs7903146 genotypes according gastric cancer 
stratified by degree of differentiation, and we observed 
that carriers of rs7903146 T allele (CT + TT vs  CC) 
had a significantly increased risk of moderate/well 
differentiated gastric cancer (dominant model, OR 
= 2.55, 95%CI: 1.35-4.80, P  = 0.004), whereas the 
rs7903146 TT genotype was associated with poorly 
differentiated gastric cancer in the recessive model 
(OR = 3.65, 95%CI: 1.25-10.62, P  = 0.018). We did 
not find association between rs12255372 SNP and the 
susceptibility of developing gastric cancer. 
CONCLUSION: TCF7L2  rs7903146 polymorphism is 
associated with gastric cancer risk in the Venezuelan 
population, and could be related to determine the 
degree of differentiation of tumor cells. 
Key words: Gastric cancer; Wnt/β-catenin pathway; 
TCF7L2 ; Single nucleotide polymorphism; Genetic 
susceptibility
© The author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: TCF7L2 transcription factor plays an important 
role in transcriptional activation induced by the Wnt/
β-catenin pathway, which is reported to be associated 
with human carcinogenesis and it is found activated in 
30%-50% of gastric cancers. TCF7L2  polymorphisms 
rs12255372 and rs7903146 are associated with a 
significant risk of type 2 diabetes and in the develop-
ment of several types of cancer. This is the first report 
of association of these TCF7L2  variants with the risk 
of gastric cancer. We conducted a case-control study 
including samples of Venezuelan patients in which 
the rs7903146 T allele was found associated with the 
risk of gastric cancer, suggesting its use as potential 
diagnosis biomarker in patients with this malignance.
Torres K, Labrador L, Valderrama E, Chiurillo MA. TCF7L2 
rs7903146 polymorphism is associated with gastric cancer: 
A case-control study in the Venezuelan population. World J 
Gastroenterol 2016; 22(28): 6520-6526  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v22/i28/6520.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v22.i28.6520
INTRODUCTION
The transcription factor 7-like 2 (TCF7L2 or TCF-4) 
gene, is located on the long arm of chromosome 
10q25.3[1]. Moreover, the TCF7L2 protein is a high 
Lisandro Alvarado (UCLA) approved this study, and 
all patients gave their written informed consent to 
participate in the study.
Genotyping
Genomic DNA was extracted from paraffin sections 
of patients’ tissues by MagneSil® Genomic Fixed 
Tissue System (Promega, United States), and from 
endoscopic biopsies using the Wizard Genomic DNA 
Purification kit (Promega, United States) following the 
manufacturer’s instructions. 
SNPs genotyping was achieved by polymerase 
chain reaction-restriction fragment length poly-
morphism (PCR-RFLP) method. We designed primers 
to detect both polymorphisms using software 
DNAMAN version 7.212 (Lynnon Corporation) in order 
to amplify shorter DNA fragment, which resulted 
more efficient when DNA extracted from paraffin-
embedded tissues was used as template. The primer 
sets included in the reactions to amplify the rs7903146 
and rs12255372 polymorphisms were: forward 
5’-ACAATTAGAGAGCTAAGCACTTTTTAGGTA-3’[23], 
 reverse 5’-CTAAGTTACTTGCCTTCCCTG-3, and 
forward 5’-GAAAGTGTATTGCTATGTCCAG-3’, reverse 
5’-CAGAGGCCTGAGTCATTATCA-3’, respectively. 
PCR reactions were performed in 25 µL reaction 
volume containing 1-2 µL of genomic DNA, 1 × Green 
GoTaq® Flexi Buffer, 1.5 µmol/L MgCl2, 0.2 µmol/L 
dNTPs, 0.6 µmol/L of each primer and 1.25 U of 
GoTaq DNA Polymerase (Promega, United States). The 
amplification conditions were: 3 min at 95 ℃; then 35 
cycles of 20 s at 95 ℃, 30 s at 59 ℃ (for rs12255372)/ 
57 ℃ (for rs7903146), and 30 s at 72 ℃; followed by 
a final extension cycle of 5 min at 72 ℃. To perform 
the allelic assignment PCR products were incubated 
at 37 ℃ overnight with a restriction enzyme, RsaI 
(New England Biolabs, United States) for rs7903146 
and Tsp509I (New England Biolabs, United States) 
for rs12255372. For rs7903146, the RsaI enzyme 
produces two fragments of 81-bp and 29-bp with 
the C allele, whereas the T allele is not cleaved, and 
its PCR products remains of 110-bp. Fragments with 
the rs12255372 G allele are not cleaved and remains 
of the original size (119-bp), moreover, the T allele 
PCR product results in two fragments of 85-bp and 
34-bp after incubating with Tsp509I enzyme. PCR 
products and restriction fragments were analyzed 
on 3% agarose gel electrophoresis with ethidium 
bromide staining. To validate the RFLP-PCR assays we 
randomly select 20% of the samples to carry out DNA 
nucleotide sequencing. Furthermore, 30 samples of 
each genotype were re-genotyped and a concordance 
of 100 was observed.
Statistical analysis
P values and ORs with 95%CI were calculated using 
multiple regression analysis adjusted by age and 
gender. A P value of < 0.05 was considered statistically 
significant when comparing differences among groups, 
and the analyses were carried out using the SPSS 11.0 
package software (SPSS Inc., United States). We used 
two-sided χ2 test to determine if genetic distributions 
were in Hardy-Weinberg equilibrium. The analysis for 
LD was estimated using the Arlequin software version 
3.5.1.2. The comparisons of genotype distributions of 
polymorphisms were performed following the codomi-
nant, dominant and recessive inheritance models, 
taking into account known risk alleles. To determine 
the best-fitting models we used the Akaike information 
criterion (AIC). Post-hoc power analyses were calculated 
using G*Power software (version 3.1). A biomedical 
statistician from the UCLA performed statistical review 
of the study. All authors accessed the data of the study 
and agreed final version of the manuscript.
RESULTS
The characteristics of the cases and controls are 
summarized in Table 1. Gastric cancer tissues included 
14 well- (11.5%), 56 moderately (45.9%), and 52 
poorly (42.6%) differentiated carcinoma. As shown in 
Table 2, the genotype distributions of rs7903146 and 
rs12255372 SNPs in the control group were in Hardy-
Weinberg equilibrium (P > 0.05). The differences 
between the groups with respect to the distribution by 
age and sex were significant; therefore we adjusted 
for these variables in the subsequent analyses of 
the relationship between polymorphisms and gastric 
cancer susceptibility. Rs7903146 and rs12255372 
SNPs were in moderate LD (D’ < 0.644; r2 < 0.33). 
Among gastric cancer cases five samples did not 
amplify with the rs12255372 primer set.
The rs7903146 TT genotype was significantly 
associated with increased risk of gastric cancer under 
both the codominant (OR = 3.61, 95%CI: 1.36-9.61, P 
= 0.01) and the recessive model (OR = 3.11, 95%CI: 
1.22-7.92, P = 0.017), after adjustment for age and 
gender (Table 2). However, the recessive model of 
inheritance was suggested as the best-fitting one by 
the AIC score. 
Furthermore, we evaluated the genotype distri-
bution of rs7903146 and rs12255372 SNPs in the 
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Table 1  Characteristics of the study population  n  (%)
Variables Controls Gastric cancer
Overall 129 122
Sexa
   Male 63 (48.8) 88 (72.1)
   Female 66 (51.2) 34 (27.9)
Agea, mean ± SD (yr) 58.81 ± 9.99 62.32 ± 14.29
Histological differentiation
   Well 14 (11.5)
   Moderated 56 (45.9)
   Poor 52 (42.6)
aP < 0.05 vs control.
Torres K et al . TCF7L2  polymorphisms associated with gastric cancer
the dominant model (CT + TT vs CC) as the best-
fitting one in the comparisons of gastritis samples with 
both groups of gastric cancer. Importantly, the post-
hoc analysis revealed that the study has acceptable 
statistical power (1 - β > 0.80 at type Ⅰ level of 0.05) 
to support the observed significant associations for 
rs7903146 genotypes. Finally, we did not identify 
any significant difference in genotype frequencies of 
rs12255372 SNP between gastric cancer and gastritis 
groups, even taking into account the degree of tumor 
differentiation (Tables 2 and 3). 
DISCUSSION
Gastric cancer is a multifactorial disease that results 
gastric cancer samples divided according to the 
degree of histological differentiation of tumors (Table 
3). To conduct these analyses, samples of well and 
moderately differentiated gastric carcinoma were 
gathered in a single group (57.4%; 70/122). Compared 
with CC genotype, rs7903146 CT heterozygous and 
TT homozygous genotypes, as well as the combined 
genotype CT + TT, had a significantly increased risk for 
moderate/well differentiated gastric cancer (ORs = 2.33, 
5.70 and 2.55, respectively), adjusted by age and 
gender (Table 3). 
Moreover, rs7903146 TT genotype was associated 
with poorly differentiated gastric cancer in the recessive 
model (OR = 3.65, 95%CI: 1.25-10.62, P = 0.018). 
However, in these analyses the AIC score suggested 
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Table 2  Association of TCF7L2 rs7903146 and rs12255372 polymorphisms with gastric cancer  n  (%)
SNP Risk allele HWE (control), 
P  value
Inheritance 
model
Genotype Control Gastric cancer OR (95%CI)1 P  value1
rs7903146 T 0.741 n = 129 n = 122
CC   73 (56.6)   56 (45.9) 1
Codominant CT   49 (38.0)   48 (39.3) 1.30 (0.75–2.25) 0.345
TT   7 (5.4)   18 (14.8) 3.61 (1.36–9.61) 0.010
Dominant CC   73 (56.6)   56 (45.9) 1
CT + TT   56 (43.4)   66 (54.1) 1.58 (0.94–2.64) 0.082
Recessive CC + CT 122 (94.6) 104 (85.2) 1
TT   7 (5.4)   18 (14.8) 3.11 (1.22–7.92) 0.017
rs12255372 T 0.053 n = 129 n = 117
GG   85 (65.9)   78 (66.7) 1
Codominant GT   35 (27.1)   32 (27.3) 1.06 (0.59–1.92) 0.841
TT   9 (7.0)   7 (6.0) 1.11 (0.38–2.25) 0.849
Dominant GG   85 (65.9)   78 (66.7) 1
GT + TT   44 (34.1)   39 (33.3) 1.06 (0.61–1.83) 0.839
Recessive GG + GT 120 (93.0) 110 (94.0) 1
TT   9 (7.0)   7 (6.0) 1.02 (0.36–2.90) 0.972
1Adjusted by age and gender; Statistical power (1-β) was calculated for all observed P values. HWE: Hardy-Weinberg equilibrium; SNP: Single nucleotide 
polymorphism.
Table 3  Distribution of TCF7L2  rs7903146 and rs12255372 single nucleotide polymorphisms according to the degree of 
histological differentiation of gastric cancer  n  (%)
SNP Inheritance 
model
Genotype Control M/W GC OR (95%CI)1 P  value1 P GC OR (95%CI)1 P  value1
rs7903146 n = 129 n = 70 n = 52
CC   73 (56.6) 25 (35.7) 1 31 (59.6) 1
Codominant CT   49 (38.0) 36 (51.4) 2.33 (1.20–4.51) 0.012 12 (23.1) 0.57 (0.26–1.23) 0.152
TT   7 (5.4)   9 (12.9) 5.70 (1.60–20.3) 0.007   9 (17.3) 2.99 (0.99–8.92) 0.050
Dominant CC   73 (56.6) 25 (35.7) 1 31 (59.6) 1
CT + TT   56 (43.4) 45 (64.3) 2.55 (1.35–4.80) 0.004 21 (40.4) 0.88 (0.45–1.71) 0.708
Recessive CC + CT 122 (94.6) 61 (87.1) 1 43 (82.7) 1
TT   7 (5.4)   9 (12.9) 2.93 (0.99–8.68) 0.053   9 (17.3) 3.65 (1.25–10.6) 0.018
rs12255372 n = 129 n = 66 n = 51
GG   85 (65.9) 38 (57.6) 1 40 (78.4) 1
Codominant GT   35 (27.1) 24 (36.3) 1.44 (0.39–5.36) 0.589   8 (15.7) 0.51 (0.21–1.21) 0.129
TT   9 (7.0) 4 (6.1) 1.63 (0.83–3.21) 0.156 3 (5.9) 0.81 (0.20–3.26) 0.770
Dominant GG   85 (65.9) 38 (57.6) 1 40 (78.4) 1
GT + TT   44 (34.1) 28 (42.4) 1.58 (0.84–3.00) 0.158 11 (21.6) 0.56 (0.26–1.22) 0.145
Recessive GG + GT 120 (93.0) 62 (93.9) 1 48 (94.1) 1
TT   9 (7.0) 4 (6.1) 1.15 (0.33–4.05) 0.823 3 (5.9) 0.87 (0.22–3.43) 0.844
1Adjusted by age and gender; Statistical power (1-β) was calculated for all observed P values. W/M: Well and moderately differentiated gastric cancer; P 
GC: Poorly differentiated gastric cancer; SNP: Single nucleotide polymorphism. 
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from the complex interplay of several host, bacterial, 
and environmental factors acting at gastric mucosa, 
that lead to the deregulation of many oncogenic 
signaling pathways[24]. Among them, the Wnt/β-catenin 
pathway is observed active in 30% to 50% of gastric 
cancer tissues and in several types of gastric cancer 
cell lines[25-27].
Available data confirmed that gain-of-function 
mutations in Wnt activators, as CTNNB1 (the gene 
that encodes β-catenin protein), and/or inactivating 
mutations and promoter hypermethylation in tumor 
suppressor genes (e.g., APC) lead to nuclear β-catenin 
accumulation and constitutive activation of the 
Wnt pathway in gastric cancer[11]. In the nucleus, 
free β-catenin binds TCF7L2 transcription factors, 
thereby modulating expression of genes (e.g., c-myc) 
implicated in proliferation, inhibition of apoptosis, tissue 
invasion and metastasis[28]. It is known that alterations 
in TCF7L2 gene and its expression, which also have 
a role in T2DM susceptibility, mediate carcinogenic 
effects through increased expression of c-myc and 
cyclin D[12,29]. Moreover, while several mutations in Wnt 
pathway components, such as APC, CTNNB1, β-TrCP, 
Axin1 and Axin2 have been implicated in gastric 
cancer[11,30], the only TCF7L2 alterations so far reported 
in gastric tumors are somatic frameshift mutations in 
the exon 14 of the gene[31,32]. 
In our work the rs7903146 TT genotype was 
related with the risk of gastric cancer in the codomi-
nant and recessive models (OR = 3.61 and 3.11, 
respectively). Interestingly, the T allele at rs7903146 
TCF7L2 is the most correlated genetic variant with 
T2DM susceptibility, which has also been associated 
with the risk for several types of cancer.
Although, case-control studies involving TCF7L2 
rs7903146 and rs12255372 polymorphisms and cancer 
susceptibility have shown contradictory results, recent 
meta-analyses revealed that the TCF7L2 rs7903146 
SNP is associated significantly with the risk of breast, 
prostate and colon cancer, as well as between the 
rs12255372 polymorphism and the susceptibility of 
breast cancer[33-36]. Moreover, the rs12255372 SNP was 
not found associated with gastric cancer risk in this 
work.
The mechanism involving TCF7L2 gene poly-
morphisms with cancer risk remains unclear, however 
the fact that TCF7L2 gene product participates in 
Wnt/β-catenin signaling pathway allows to envisage 
their participation in carcinogenesis. Moreover, recent 
evidence suggests that TCF7L2 polymorphisms 
may be related with changes in expression levels of 
its gene product. Gaulton et al[37] showed that the 
TCF7L2 intronic SNP rs7903146 is located in an islet 
FAIRE (Formaldehyde-Assisted Isolation of Regulatory 
Elements)-enriched site and affects chromatin state and 
enhancer function. Furthermore, TCF7L2 rs7094463, 
rs10749127, and rs11196224 SNPs, which correlate 
with recurrence of prostate cancer in patients that 
were treated with radical prostatectomy, are located 
in potential transcriptional regulatory regions[38]. It is 
suggested that these DNA polymorphisms can alter 
the transcription factor binding sites and thus affect the 
TCF7L2 expression level.
Our results also suggest that the rs7903146 
polymorphism (T allele) may be involved in defining 
the degree of differentiation of tumor cells. However, 
we cannot rule out that the small number of gastric 
adenocarcinoma samples with the TCF7L2 rs7903146 
TT genotype could drive the observed association with 
the degree of differentiation of tumor cells when it was 
used codominant and recessive models. The association 
of genetic and epigenetic alterations with subtypes 
of gastric carcinoma suggests particular interactions 
for the development of a gastric tumor with specific 
degree of differentiation[39-41]. Furthermore, due to the 
aggressiveness of gastric cancer has been associated 
with the degree of differentiation of tumor cells, the 
evaluation of this aspect should be considered in the 
management of gastric cancer[22,42].
In conclusion, this is the first study that examines 
the role of TCF7L2 rs7903146 and rs12255372 SNPs 
related to susceptibility of gastric cancer in a Vene-
zuelan high-risk population. Moreover, after adjust-
ment for age and gender, we found that the rs7903146 
polymorphism was significantly associated with the 
genetic susceptibility to gastric cancer in the Venezuelan 
population. This work gives additional support to 
understanding the participation of alterations in the 
Wnt/β-catenin pathway in the gastric carcinogenesis, 
and could represent a contribution to the identification 
of novel biomarkers for detection and/or monitoring 
progression or recurrence of gastric cancer. However, 
although the post-hoc analysis indicates that there 
was enough statistical power to support the observed 
associations, analysis of a larger sample size is 
needed to corroborate the participation of the TCF7L2 
polymorphisms in the risk of gastric cancer. 
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